Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib plus Anastrozole in Postmenopausal ER+ Breast Cancer
NCT01216176Phase 2Completed
- Start
- Oct 2008
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of saracatinib in breast cancer (3 cohorts). Primary endpoints: Maximum Tolerated Dose and Clinical Response at Cycle 6. Started Oct 2008; status: completed.
02
Drugs
saracatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01216176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01216176.